BPC-157 Dosage & Reconstitution Research Guide

BPC-157 is typically supplied as a freeze-dried peptide that needs to be reconstituted before it can be used in a study. This guide covers how dosing shows up in the published research, how that mixing (reconstitution) is generally done, how to store it, and a few handling notes worth knowing. It’s written to explain the science in plain terms — not as instructions for using it on a person or animal.

Dosing in the Literature

BPC-157’s dosing story looks different from something like tirzepatide or retatrutide, which at least have human clinical trial doses to reference. BPC-157 doesn’t — its dosing literature is almost entirely preclinical.

• Most published studies dose BPC-157 in animal models (typically rodents) on a body-weight basis — commonly in the microgram-per-kilogram range, which is a much smaller scale than the milligram doses used for larger peptides.
• Administration routes in the research literature vary by study, including injection (subcutaneous or intraperitoneal) and, in some gut-healing research, oral or intragastric delivery.
• The small amount of human data that exists — a retrospective study and a single Phase I trial — doesn’t provide a validated, publicly established human dosing schedule the way an approved drug’s label would.
• Because doses in the literature are scaled to specific animal models and study designs, there’s no single “BPC-157 dose” that the research supports as a general reference point.

The takeaway: any dose referenced online as “the BPC-157 dose” is almost certainly extrapolated or borrowed from a specific animal study, not drawn from an established human dosing standard — because that standard doesn’t exist yet. Any dose used in a lab setting should be determined independently based on the specific study, species, and protocol.

Reconstitution Step by Step

“Reconstitution” means turning the freeze-dried peptide back into a liquid at a known strength, so it can be measured accurately. Here’s generally how that’s done:

1. Assemble your supplies. Have the peptide vial, a bottle of bacteriostatic water, alcohol swabs, and a clean syringe on hand before you begin.
2. Disinfect the stoppers. Wipe the rubber top of the peptide vial with an alcohol swab and clear off your work surface.
3. Work out the concentration. Strength equals the peptide amount divided by the liquid volume — a 5 mg vial reconstituted with 2 mL comes to 2.5 mg per mL, while 5 mL brings it down to 1 mg per mL.
4. Pull the water into the syringe. Draw up the volume you calculated, removing any air bubbles as you go.
5. Ease it into the vial. Angle the stream toward the inside wall so the liquid runs down the glass instead of striking the powder head-on, which limits foaming.
6. Swirl rather than shake. BPC-157 holds up reasonably well compared to many peptides, but vigorous agitation still risks breaking down its structure, so a gentle rotation is enough to dissolve it.
7. Look it over. The finished solution should be clear with no floating particles; if it isn’t, don’t use it.
8. Mark the vial. Jot down the date and the concentration you just worked out.
9. Get it into storage without delay — see the section below for specifics.

Storage and Stability

Before mixing: BPC-157 is notably stable for a peptide — it’s known to hold up well even at room temperature for short periods, which is part of why it drew scientific interest in the first place. Even so, standard practice is to keep it frozen, dry, and away from light until it’s needed, to preserve it over the long term.

After mixing: Once in liquid form, it’s less stable than in freeze-dried form, though its underlying resilience means it tends to hold up reasonably well compared to more fragile peptides. The usual approach is still to keep it refrigerated, protected from light, and to use it within a defined window based on the specific setup rather than relying on its stability reputation alone.

Avoid repeated freeze-thaw cycles. Each cycle adds some degree of damage, even to a relatively stable peptide. Splitting a solution into smaller portions right after mixing helps avoid this if multiple uses are planned.

Don’t rely on generic timelines. Actual stability depends on the diluent, concentration, and storage conditions used in a given protocol — treat published shelf-life figures as a starting point, not a guarantee.

Handling Notes

• Using the wrong liquid. Tap water or regular saline isn’t the same as sterile bacteriostatic water, and can introduce contamination or affect stability.
• Shaking instead of swirling. This is one of the most common ways people accidentally damage a peptide, even a relatively stable one like BPC-157.
• Squirting liquid straight onto the powder. This can cause foaming and stress the peptide before it’s even dissolved.
• Treating an animal-study dose as a human reference point. Doses reported in the literature are scaled to specific animal models — they don’t convert cleanly to a “safe” or “effective” human amount.
• Skipping the certificate of analysis. Always worth checking what’s actually in a batch before using it, particularly for a compound with as much unregulated market activity as BPC-157 has.
• Not labeling vials clearly. It’s easy to lose track of strength and age without clear notes, especially across multiple batches or studies.

Research Use Disclaimer

BPC-157 remains unapproved by the FDA and every other health authority, and it is not a drug, food, supplement, or cosmetic; the World Anti-Doping Agency also bans it for competitive sports. Its compounding status has shifted since 2023, when it was placed — alongside TB-500 — on an FDA list of substances deemed too high-risk for pharmacy compounding. HHS Secretary Robert F. Kennedy Jr. reversed that listing earlier in 2026, which led to a July 24, 2026 vote by the FDA’s Pharmacy Compounding Advisory Committee, a panel that had recently added several members with peptide-industry ties: 8–6, with one abstention, in favor of permitting BPC-157 in compounded prescriptions. That result came despite pushback from FDA staff scientists, who noted the five supporting studies were short in duration, small in sample size, and used doses “likely exploratory in nature.” Because the committee’s recommendation isn’t binding, none of this changes BPC-157’s current unapproved status. Everything in this guide is meant for general educational purposes, based on what’s published in the available research literature. None of it is medical advice, a treatment plan, or instructions for using BPC-157 on a person or animal.

Blueprint Sciences supplies BPC-157 with a certificate of analysis for every batch, strictly for laboratory research use. You can view the current listing here: BPC-157 – Research Use Only.

Using BPC-157 outside of a legitimate research setting isn’t something we support or recommend — the evidence needed to support a safe, established human dose simply isn’t there yet.